ALEXANDRIA, Virginia — The American Association for the Study of Liver Diseases (AASLD) is pleased to share the Special Issue on Cholestasis published by HEPATOLOGY, the premier publication in the field of liver disease.
Cholestatic liver diseases—such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and IgG4-related cholangitis—pose a significant but often underrecognized burden. Unlike viral hepatitis or liver cancer, their epidemiology and economic impact remain less defined.
In this issue, experts review the latest data on disease prevalence, quality of life, and healthcare costs, offering vital information to guide future policy and research priorities.
"This important collection highlights critical progress in pathophysiology, disease mechanisms, and therapeutic strategies, providing valuable insights for researchers, clinicians, and healthcare policymakers,” said HEPATOLOGY Editor-in-Chief Gregory J. Gores, MD, FAASLD, Mayo Clinic, Rochester.
Key highlights include insights into the epidemiology, burden, and quality-of-life impact of cholestatic liver diseases, advances in understanding immune mechanisms and cholangiocyte biology, and emerging therapeutic strategies, including new FDA-approved treatments for PBC.
It also highlights novel perspectives on PSC pathogenesis, genetic cholangiopathies in pediatrics, drug-induced cholestatic injury, and challenges of disease recurrence after transplantation.
“By shining a bright spotlight on cholestatic liver diseases, this thematic issue not only captures the latest progress but also sets the stage for new lines of investigation and therapeutic development,” said HEPATOLOGY Deputy Editor Harmeet Malhi, MBBS, FAASLD, Mayo Clinic, Rochester.
Watch the video commentary from Cynthia Levy, MD, FAASLD of the University of Miami and view the full collection in the latest issue of HEPATOLOGY.
###
About AASLD
The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients and advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
About HEPATOLOGY
The premier publication in the field of liver disease, HEPATOLOGY publishes original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Follow the journal on X at @HEP_Journal.